Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim study supports combination blood pressure treatment

Boehringer Ingelheim study supports combination blood pressure treatment

3rd September 2010

Boehringer Ingelheim has published a new study which highlights the effectiveness of a combination of telmisartan and amlodipine in treating high blood pressure.

The company conducted an eight-week trial to gauge the efficacy of a single-pill combination of the two compounds among patients with severe hypertension.

According to data presented at the Scientific Meeting of the European Society of Hypertension, this combined treatment delivered superior blood pressure reductions compared to either compound on its own.

Dr Sarah Jarvis, GP and fellow of the Royal College of General Practitioners and Women's Health, said this treatment could help to curb rates of cardiovascular disease and will be particularly important to sufferers of hypertension and diabetes.

She added: "Well-tolerated treatment options that reduce the pill burden for my patients will lead to better management of their hypertension and lead to better outcomes."

Earlier this week, Boehringer Ingelheim was granted a priority Food and Drug Administration review for its new atrial fibrillation treatment dabigatran etexilate, which recognises the advances the drug offers over currently available therapies.ADNFCR-8000103-ID-800050713-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.